Brokerages Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $34.80

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the […]

Leave a Reply

Your email address will not be published.

Previous post Unilever PLC (NYSE:UL) Receives $66.33 Consensus Target Price from Analysts
Next post Bahrain Q1 2025: Toyota Land Cruiser leads the way, Jetour T2 up to #4